Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 6;26(15):7591.
doi: 10.3390/ijms26157591.

Revitalizing Colchicine: Novel Delivery Platforms and Derivatives to Expand Its Therapeutic Potential

Affiliations
Review

Revitalizing Colchicine: Novel Delivery Platforms and Derivatives to Expand Its Therapeutic Potential

Natallia V Dubashynskaya et al. Int J Mol Sci. .

Abstract

Colchicine is a potent alkaloid with well-established anti-inflammatory properties. It shows significant promise in treating classic immune-mediated inflammatory diseases, as well as associated cardiovascular diseases, including atherosclerosis. However, its clinical use is limited by a narrow therapeutic window, dose-limiting systemic toxicity, variable bioavailability, and clinically significant drug-drug interactions, partly mediated by modulation of P-glycoprotein and cytochrome P450 3A4 metabolism. This review explores advanced delivery strategies designed to overcome these limitations. We critically evaluate lipid-based systems, such as solid lipid nanoparticles, liposomes, transferosomes, ethosomes, and cubosomes; polymer-based nanoparticles; microneedles; and implants, including drug-eluting stents. These systems ensure targeted delivery, improve pharmacokinetics, and reduce toxicity. Additionally, we discuss chemical derivatization approaches, such as prodrugs, codrugs, and strategic ring modifications (A-, B-, and C-rings), aimed at optimizing both the efficacy and safety profile of colchicine. Combinatorial nanoformulations that enable the co-delivery of colchicine with synergistic agents, such as glucocorticoids and statins, as well as theranostic platforms that integrate therapeutic and diagnostic functions, are also considered. These innovative delivery systems and derivatives have the potential to transform colchicine therapy by broadening its clinical applications while minimizing adverse effects. Future challenges include scalable manufacturing, long-term safety validation, and the translation of research into clinical practice.

Keywords: codrug; colchicine; drug delivery systems; immune-mediated inflammatory diseases; prodrug.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Chemical structure of colchicine (adapted from [28]).
Figure 2
Figure 2
Mechanism of action of colchicine (adapted from [28]).
Figure 3
Figure 3
The diversity of colchicine delivery systems.
Figure 4
Figure 4
Synthesis of thiocolchicine and 1,2,3-demethylthiocolchicine (adapted from [27]).
Figure 5
Figure 5
Variation of the C-1 substituent of colchicine (adapted from [27]).
Figure 6
Figure 6
Synthesis of 4-chloro-, 4-bromo-, and 4-iodocolchicine (adapted from [169]).
Figure 7
Figure 7
Synthesis of deacetylthiocolchicine from thiocholcine derivative (adapted from [27]).
Figure 8
Figure 8
Synthesis of triazoles derived from colchicine, allocolchicine, and N-acetylcolchinol (adapted from [27,187]).
Figure 9
Figure 9
Examples of colchicinoids synthesized by “click” conjugation (adapted from [186,188]).
Figure 10
Figure 10
Structural modifications carried out on colchicine to produce 7-triazoles of 10-N-methylaminocolchicine (adapted from [190]).
Figure 11
Figure 11
Synthesis of N-acetylcolchinol from colchicine (adapted from [27]).
Figure 12
Figure 12
Substitution with thiomethyl groups in C-10 (adapted from [195]).
Figure 13
Figure 13
Colchicine derivatives with amino or related functional groups at C-10 (adapted from [196]).

References

    1. Monteleone G., Moscardelli A., Colella A., Marafini I., Salvatori S. Immune-mediated inflammatory diseases: Common and different pathogenic and clinical features. Autoimmun. Rev. 2023;22:103410. doi: 10.1016/j.autrev.2023.103410. - DOI - PubMed
    1. McInnes I.B., Gravallese E.M. Immune-mediated inflammatory disease therapeutics: Past, present and future. Nat. Rev. Immunol. 2021;21:680–686. doi: 10.1038/s41577-021-00603-1. - DOI - PMC - PubMed
    1. Scherlinger M., Richez C., Tsokos G.C., Boilard E., Blanco P. The role of platelets in immune-mediated inflammatory diseases. Nat. Rev. Immunol. 2023;23:495–510. doi: 10.1038/s41577-023-00834-4. - DOI - PMC - PubMed
    1. Schett G., McInnes I.B., Neurath M.F. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N. Engl. J. Med. 2021;385:628–639. doi: 10.1056/NEJMra1909094. - DOI - PubMed
    1. Galkina E., Ley K. Immune and inflammatory mechanisms of atherosclerosis (*) Annu. Rev. Immunol. 2009;27:165–197. doi: 10.1146/annurev.immunol.021908.132620. - DOI - PMC - PubMed

LinkOut - more resources